Hyderabad, Oct. 14 -- Bristol Myers Squibb (BMS) today announced the launch of Kopozgo(R) (Mavacamten) in India -- the first and only oral, selective cardiac myosin inhibitor approved in the country for the treatment of adults with symptomatic New York Heart Association (NYHA) Class II-III obstructive hypertrophic cardiomyopathy (OHCM).
Symptomatic obstructive HCM is an often-inherited heart disease that can be a chronic, debilitating and progressive condition where patients may experience symptoms of shortness of breath, dizziness and fatigue as well as serious, life-altering complications, including heart failure, arrhythmias, stroke and in rare cases (~1%) sudden cardiac death.
It affects about 1 in 500 people worldwide, and it is esti...